A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.
In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardised rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.
Excision of a primary tumour remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.
“The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole”, says Professor Renaldas Raišutis, head of the team behind the research at Kaunas University of Technology.
In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analysing complex data on skin tumours recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.
“An efficient diagnosis of an early-stage malignant skin tumour could save critical time: more patients could be examined and more of them could be saved”, says Prof Raišutis.
According to Prof Raišutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.
Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.
The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- How The Guidelines Have Changed Regarding Lung Cancer Early Detection Effortson April 29, 2021 at 2:21 pm
Lung cancer is the leading cause of U.S. cancer deaths. The U.S. Preventive Services Task Force has expanded screening guidelines in an effort to help increase early detection rates. On CBSN Denver, ...
- When cancer strikes those under 40, race matterson April 28, 2021 at 11:40 am
(HealthDay)—Young Black and Hispanic cancer patients face poorer survival odds than their white counterparts, even from some cancers that are highly curable, a new study finds.
- Earlier Detection of Cancer in Minorities Holds Promise to Close Persistent Disparities in Health Outcomeson April 28, 2021 at 9:25 am
Despite significant advancements in the detection and treatment of cancer in recent decades, cancer is still the second-leading cause of death in the United States. Racial and ethnic minorities ...
- Castle fortifies position in skin cancer detection with $32.5M Myriad Mypath acquisitionon April 27, 2021 at 3:20 pm
Castle Biosciences Inc. deepened the moat around its position in melanoma diagnostics with the acquisition of Myriad Mypath LLC from Myriad Genetics Inc. The acquisition gives Castle (NASDAQ:CSTL) the ...
- DermTech rises 18% on report Cigna covering early melanoma detection teston April 27, 2021 at 8:03 am
Shares of DermTech (DMTK) are up more than 18% in morning trading amid speculation that Cigna will cover the company's PLAplus early detection test for melanoma.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Stories of Loss and Survival with Melanomaon April 30, 2021 at 9:12 am
My story of loss began in August 2004 when my wife was diagnosed with melanoma. An unnoticed spot on her lower back scabbed over and bled. A biopsy in the office came back as testing positive as ...
- Dear Dr. Roach: Agent Orange linked to some cancers, but not melanomaon April 29, 2021 at 3:00 am
Your recent column on melanoma piqued my interest. My husband was exposed to Agent Orange in Vietnam in 1968. He had a melanoma on his neck removed ...
- AHN building new melanoma, skin cancer centeron April 28, 2021 at 9:15 pm
Jessica Rogowicz grew up playing outside and spending lots of time in the sun including yearly beach vacations in Ocean City, Md.
- Olatec Therapeutics Announces Results Showing Dapansutrile Reduces Tumor Growth in a Mouse Model of Melanomaon April 28, 2021 at 11:48 am
Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected cancer models.
- Dr. Davies on Managing Melanoma During the COVID-19 Pandemicon April 28, 2021 at 10:25 am
Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic. Michael A. Davies, MD, PhD, the Anne and John Mendelsohn Chair in Cancer Research; professor and chair ...